OXB vs. GNS, ONT, ERGO, SLN, PRTC, HZD, AVCT, VRP, FARN, and ARIX
Should you be buying Oxford Biomedica stock or one of its competitors? The main competitors of Oxford Biomedica include Genus (GNS), Oxford Nanopore Technologies (ONT), Ergomed (ERGO), Silence Therapeutics (SLN), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Avacta Group (AVCT), Verona Pharma plc (VRP.L) (VRP), Faron Pharmaceuticals Oy (FARN), and Arix Bioscience (ARIX). These companies are all part of the "biotechnology" industry.
Oxford Biomedica vs. Its Competitors
Oxford Biomedica (LON:OXB) and Genus (LON:GNS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.
Oxford Biomedica presently has a consensus target price of GBX 558, suggesting a potential downside of 7.00%. Genus has a consensus target price of GBX 2,900, suggesting a potential upside of 14.62%. Given Genus' stronger consensus rating and higher possible upside, analysts clearly believe Genus is more favorable than Oxford Biomedica.
In the previous week, Oxford Biomedica had 3 more articles in the media than Genus. MarketBeat recorded 4 mentions for Oxford Biomedica and 1 mentions for Genus. Oxford Biomedica's average media sentiment score of 1.54 beat Genus' score of 0.96 indicating that Oxford Biomedica is being referred to more favorably in the media.
Oxford Biomedica has a beta of 1.09, suggesting that its share price is 9% more volatile than the S&P 500. Comparatively, Genus has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.
32.4% of Oxford Biomedica shares are held by institutional investors. Comparatively, 63.4% of Genus shares are held by institutional investors. 41.9% of Oxford Biomedica shares are held by insiders. Comparatively, 0.7% of Genus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Genus has a net margin of 1.18% compared to Oxford Biomedica's net margin of -145.98%. Genus' return on equity of 1.41% beat Oxford Biomedica's return on equity.
Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.
Summary
Genus beats Oxford Biomedica on 10 of the 16 factors compared between the two stocks.
Get Oxford Biomedica News Delivered to You Automatically
Sign up to receive the latest news and ratings for OXB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding OXB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Oxford Biomedica Competitors List
Related Companies and Tools
This page (LON:OXB) was last updated on 10/26/2025 by MarketBeat.com Staff